Proteinopathies in Neurodegenerative Diseases

Introduction to Proteinopathies

• The American Academy of Neurology and the Alzheimer's Association recommend that Alzheimer's disease is characterized by both beta-amyloid and tau pathology, while Parkinson's disease features alpha-synuclein, and Dementia with Lewy Bodies is primarily an alpha-synucleinopathy with co-existing Alzheimer's pathology 1, 2, 3

Alzheimer's Disease

• The National Institute on Aging and the Alzheimer's Association state that AD pathology requires both beta-amyloid deposition in plaques and tau deposition in neurofibrillary tangles for definitive pathological diagnosis, with the current pathological criteria mandating evidence of both proteins 1, 2, 4
• The European Alzheimer's Disease Consortium notes that beta-amyloid deposition appears to precede tau pathology temporally, with amyloid changes occurring 25-30 years before symptom onset, and tau pathology correlates more strongly with clinical symptoms and neurodegeneration than amyloid alone 5

Frontotemporal Lobar Degeneration

• The International Society for Frontotemporal Dementia states that FTLD is heterogeneous and includes multiple pathological subtypes, including tau-positive variants like Pick's disease, which features Pick bodies, and TDP-43 proteinopathies 3, 6
• The American Academy of Neurology recommends that Pick bodies specifically refer to tau-positive inclusions in Pick's disease, a subset of FTLD 7

Chronic Traumatic Encephalopathy

• The National Institute of Neurological Disorders and Stroke states that CTE is definitively a tauopathy characterized by a unique pattern of phosphorylated tau deposition, and diagnosis requires neuropathological examination demonstrating this distinctive pattern 8

Diagnostic Considerations

• The Alzheimer's Association notes that elevated p-tau217 is highly specific for AD pathology and not significantly elevated in other tauopathies, and when p-tau217 is normal but cognitive impairment exists, non-AD diagnoses like frontotemporal dementia should be considered 7
• The American Academy of Neurology recommends that the presence of one pathology doesn't exclude others, as mixed pathology is the rule rather than exception in elderly patients 6
• The European Federation of Neurological Societies states that tau elevation is not specific to AD, and occurs in prion diseases, CTE, and some FTLD variants, and alpha-synuclein defines synucleinopathies but these frequently have co-existing AD pathology 1, 4, 8

Conditions that Elevate TAU and p-TAU in Cerebrospinal Fluid Beyond Alzheimer's Disease

Introduction to Tauopathies

• The American Academy of Neurology suggests that various neurodegenerative conditions and acute brain injuries can increase TAU and p-TAU in cerebrospinal fluid, including frontotemporal dementia, chronic traumatic encephalopathy, prion diseases, vascular dementia, and acute brain lesions 9

Tauopathies

• The National Institute of Neurological Disorders and Stroke indicates that frontotemporal lobar degeneration (FTLD) includes multiple pathological tau-positive subtypes, such as Pick's disease, which presents with Pick bodies (specific tau-positive inclusions) 9
• The European Federation of Neurological Societies notes that in the cerebrospinal fluid of patients with FTLD, an isolated increase in TAU without a reduction in amyloid-β42 is observed, favoring the diagnosis of the behavioral variant of frontotemporal dementia over Alzheimer's disease 9
• The International Society for Frontotemporal Dementias states that the p-tau/total TAU ratio tends to be different in FTLD compared to Alzheimer's disease, with a less pronounced increase in p-tau 9

Diagnostic Considerations

• The American College of Neuropsychopharmacology suggests that the combination of elevated TAU with reduced amyloid-β42 indicates Alzheimer's disease, while isolated elevated TAU (without reduced amyloid-β42) favors FTLD 9

CSF Tau Biomarkers in Neurodegenerative Disease Diagnosis

Diagnostic Differentiation of Creutzfeldt‑Jakob Disease (CJD)

• In patients with suspected sporadic CJD, the cerebrospinal fluid (CSF) total‑tau to phosphorylated‑tau ratio (t‑tau/p‑tau) (or its inverse) provides extremely high diagnostic accuracy (area under the curve = 0.98–0.99) for distinguishing CJD from other neurological disorders, including rapidly progressive Alzheimer disease (AD).  10
• In CJD the t‑tau/p‑tau ratio is markedly elevated because total‑tau concentrations are often > 1250–1400 pg/mL while phosphorylated‑tau rises disproportionately less.  10
• When CSF total‑tau exceeds 1250 pg/mL, calculation of the t‑tau/p‑tau ratio is recommended; a very high ratio strongly supports CJD as the primary diagnosis.  10

Use of CSF Biomarkers in Established Dementia

• For patients with a confirmed dementia syndrome, CSF biomarker testing (including t‑tau, p‑tau, and Aβ42) should be employed as an adjunct to clinical assessment, particularly in atypical or diagnostically uncertain cases, to confirm or exclude AD as the underlying cause.  11

Role of Biomarkers in Mild Cognitive Impairment (MCI)

• In individuals with symptomatic MCI, an elevated p‑tau/Aβ42 ratio predicts conversion to AD dementia with high accuracy, supporting its use for risk stratification.  12
• CSF biomarker panels (p‑tau, total‑tau, Aβ42) are recommended for symptomatic MCI patients when anti‑amyloid therapies are being considered, to detect underlying AD pathology.  [12][11]

Limitations and Specificity of Total‑Tau

• Elevated CSF total‑tau is not specific for AD; it is also observed in CJD, chronic traumatic encephalopathy, certain frontotemporal lobar degeneration variants, vascular dementia, acute brain injuries, inflammatory CNS diseases, and CNS neoplasms, which reduces its diagnostic specificity when used alone.  10
• Inflammatory and neoplastic central nervous system disorders can raise total‑tau levels, further limiting the utility of isolated total‑tau measurements.  10

Assay Variability and Cut‑off Recommendations

• No universal consensus exists on the optimal ELISA platform or cut‑off value for CSF total‑tau; suggested thresholds range from > 1072 pg/mL to > 1400 pg/mL, reflecting inter‑assay variability.  10

Principles for Clinical Interpretation

• CSF biomarker results must always be interpreted within the full clinical context of the patient and should never replace a comprehensive neurological evaluation.  13